BPC-157 (oral)
Status
No approved product. No FDA-approved labeling exists. The FDA's 2023 placement of BPC-157 in Category 2 of its interim 503A categories concerned the substance and was not specific to the route. In July 2026 the FDA's Pharmacy Compounding Advisory Committee recommended adding it to the 503A bulk drug substances list. That is a recommendation to the agency, not a rule: no proposed rule had followed at the time of this compilation, so it is still not on the 503A bulks list, and the recommendation did not approve any product or change the status of anything already being sold.
What it is
An oral capsule form of BPC-157 aimed at gut tissue specifically.
What published research measured
The same pentadecapeptide as injected BPC-157, taken by mouth. The oral route has its own rodent literature — much of the original gut work by Sikiric's group used oral or intragastric administration and reported protection in models of inflammatory bowel disease and NSAID-induced gut injury — so oral dosing is not simply an assumption borrowed from the injectable form. What does not exist is any human pharmacokinetic study establishing whether the intact peptide survives gastric acid and intestinal proteases in people, or what fraction reaches the circulation. A peptide that acts locally in the gut lumen does not need to be absorbed to act there, but any claim about systemic effects from an oral capsule requires absorption data that has not been published.
Source
Sikirić et al., oral and intragastric rodent gut-protection literature · FDA 2023 bulk substances determination for BPC-157
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.